Business
ALR TECHNOLOGIES TO RELAUNCH THE GLUCURVE PET CGM IN JANUARY 2026
ALR Technologies SG Ltd ("ALRT" or the "Company") (OTC: ALRTF), the diabetes management company, announces the successful completion of internal manufacturing testing on the GluCurve Pet CGM ("GluCurve") showing accuracy results comparative to the leading veterinary Blood Glucose Meter ("BGM") and scheduling of its relaunch into the Canadian market for January 2026.
About this update from Alr Technologies Sg Ltd.
[{"type":"text","content":"SINGAPORE, Dec. 8, 2025 /PRNewswire/ -- ALR Technologies SG Ltd ("ALRT" or the "Company") (OTC: ALRTF), the diabetes management company, announces the successful completion of internal manufacturing testing on the GluCurve Pet CGM ("GluCurve") showing accuracy results comparative to the leading veterinary Blood Glucose Meter ("BGM") and scheduling of its relaunch into the Canadian market for January 2026.","length":448,"tagName":"p"},{"type":"text","content":"GluCurve is the first and only diabetic monitoring system built specifically for veterinary use on cats and dogs. A pet-friendly Continuous Glucose Monitor ("CGM") sensor is painlessly attached to the pet and provides blood sugar levels every 3 minutes for up to 14 days. Pet owners can view the blood sugar readings on the GluCurve Pet CGM app. In addition, the blood sugar readings are uploaded to the ALRT Veterinary Web Portal, where they are displayed for the veterinarian to easily manage patients and adjust insulin dosing, either remotely or in person.","length":570,"tagName":"p"},{"type":"text","content":"Joe Stern, Head of Animal Health at ALRT, states, "Based on the most commonly accepted diabetes prevalence rate studies and pet population surveys, we estimate the potential market size for the GluCurve to be between 150,000-300,000 units per year in Canada, 2,000,000-3,000,000 units per year in the United States, and a further 2,000,000-3,000,000 units per year in Europe. You cannot prick the finger of a cat or dog to check blood sugar as you would with a human, and even when you can draw blood from their ear, paw, or vein, a spot check of this nature does not provide the data needed to properly dose insulin or see trends as a CGM would. We believe this is why we have received so much interest and demand for the GluCurve Pet CGM from veterinarians, pet owners, and animal health companies, because there is a desperate need for a holistic product like ours to manage diabetic pets.","length":897,"tagName":"p"},{"type":"text","content":"Mr. Stern continued, "We are thrilled to be partnered with CGM Medical Technology Shenzhen Ltd. on the manufacturing of CGM units for GluCurve and the development of a CGM for the human market. We have been working side by side with them to build out their manufacturing capabilitie...